Carfilzomib produced significant clinical benefit in multiple myeloma

Share this article:

A study involving 30 cancer centers in the United States and Canada yielded durable responses to and an acceptable tolerability profile for carfilzomib (Kyprolis), which was approved last month by the FDA for the treatment of advanced multiple myeloma. The results of this trial were published online ahead of print by the journal Blood a few days later.

In the open-label, single-arm, phase 2b study, a team led by David S. Siegel, MD, PhD, chief of multiple myeloma at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey, evaluated this next-generation, selective proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Carfilzomib 20 mg/m2 was administered intravenously twice weekly for 3 of 4 weeks, and then in doses of 27 mg/m2 for up to 12 cycles.

The 266 evaluable patients had received at least two prior therapies, including bortezomib, lenalidomide, and thalidomide. Most patients (95%) had not responded to their last therapy, and 80% were refractory to or intolerant of both bortezomib and lenalidomide.

With carfilzomib, overall response rate was 23.7%, with a median duration of response of 7.8 months and a median overall survival of 15.6 months. Adverse events were manageable without cumulative toxicities; common adverse events were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). A total of 33 patients (12.4%) experienced peripheral neuropathy, primarily grades 1 and 2, and the same number of patients withdrew from the study due to an adverse event.

The researchers concluded that durable responses and the acceptable tolerability profile in this heavily pretreated population demonstrated the potential of carfilzomib to offer meaningful clinical benefit, particularly given the limited number of treatment options available to persons with advanced-stage multiple myeloma and the diminished prospects for retreatment once a therapy has been used.


Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.